Breast最新文献

{"title":"P028: Confronting Barriers in HER2-Positive Metastatic Breast Cancer: Insights from a Phase II Trial of Inetetamab, Pyrotinib, and Chemotherapy","authors":"J. Zhao, Z. Zhou, L. Ding, J. Ye, T. Long, G. Zou, Y. Cai, J. Chai, H. Yao, Y Wang","doi":"10.1016/j.breast.2025.103915","DOIUrl":"10.1016/j.breast.2025.103915","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103915"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P002: Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial","authors":"C.S. Rubenstein, N. Turner, J.S. Reis-Filho, M.P. Goetz, C. Desmedt, S. Chandarlapaty, H. Sasano, C.L. Arteaga, S. Loi, S.L. Graff, D. Liu, V. Rodrik-Outmezguine, A. Sireci, H. Won, L.M. Litchfield, M. Munoz, S Johnston","doi":"10.1016/j.breast.2025.103896","DOIUrl":"10.1016/j.breast.2025.103896","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103896"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P031: Objective Response to Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study","authors":"A. Boudersa, A. Bouguettaya, N Kouadri","doi":"10.1016/j.breast.2025.103917","DOIUrl":"10.1016/j.breast.2025.103917","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103917"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them","authors":"L. Foffano ,&nbsp;L. Cucciniello ,&nbsp;E. Nicolò ,&nbsp;I. Migliaccio ,&nbsp;C. Noto ,&nbsp;C. Reduzzi ,&nbsp;L. Malorni ,&nbsp;M. Cristofanilli ,&nbsp;L. Gerratana ,&nbsp;F. Puglisi","doi":"10.1016/j.breast.2024.103863","DOIUrl":"10.1016/j.breast.2024.103863","url":null,"abstract":"<div><div>CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR + HER2 negative (HER2-) metastatic breast cancer (BC) when combined with endocrine therapy. Nonetheless, despite significant research efforts, the mechanisms of de novo and acquired resistance to CDK4/6i have not yet been fully elucidated, highlighting the need for a deeper understanding of these process. Additionally, the importance of dissecting CDK4/6i resistance from endocrine resistance for personalized treatment is increasingly recognized.</div><div>Liquid biopsy has emerged as a minimally invasive tool for identifying circulating biomarkers of resistance through the integration of multiparametric and dynamic assessments that encompass ctDNA, CTCs, exosomes, and epigenetic ctDNA alterations, representing a promising perspective for the clinical characterization of treatment resistance and guiding post-progression strategies to improve patient outcomes.</div><div>Aim of this review is summarize potential mechanisms of CDK4/6i resistance, along with the advantages of using liquid biopsy to identify resistance biomarkers in HR+/HER2- MBC patients treated with CDK 4/6 inhibitors.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103863"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncological outcomes following extreme oncoplastic breast conserving surgery (eOPBCS) for locally advanced breast cancer (LABC): A systematic review and meta-analysis","authors":"Megan Chua Wern Ee ,&nbsp;Ashley Lee Shi Hui ,&nbsp;Wong Hung Chew ,&nbsp;Emmeline Elaine Cua-Delos Santos ,&nbsp;Sean Li Siwei ,&nbsp;Sng Ming Xian ,&nbsp;Qin Xiang Ng ,&nbsp;Serene Goh Si Ning","doi":"10.1016/j.breast.2024.103869","DOIUrl":"10.1016/j.breast.2024.103869","url":null,"abstract":"<div><h3>Introduction</h3><div>Locally advanced breast cancer (LABC) accounts for 5 % of new breast cancer diagnoses in developed countries and 30–60 % in developing regions. Historically, treatment relied on mastectomy guided by the Halstedian theory. Advances in neoadjuvant chemotherapy (NACT), breast-conserving surgery (BCS), and radiation have transformed treatment into a multimodal approach. Extreme oncoplastic BCS (eOPBCS) has expanded the boundaries of BCS, enabling large-volume resections with breast reshaping. However, its oncologic outcomes compared to mastectomy remain unclear, particularly in LABC.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis were conducted following PRISMA guidelines (PROSPERO: CRD42024535182). Studies involving eOPBCS for LABC were reviewed, and those comparing outcomes with mastectomy were included in the meta-analysis. The primary outcomes were overall survival (OS), disease-free survival (DFS), and local recurrence rates (LRR). Data were synthesized using a random-effects model.</div></div><div><h3>Results</h3><div>Of 866 identified studies, 33 were included in the systematic review and 4 in the meta-analysis, involving 2902 patients with LABC. Among them, 16.1 % underwent eOPBCS. Patients receiving eOPBCS were younger, had larger tumours, and more frequently underwent axillary clearance. The pooled hazard ratio (HR) for OS comparing mastectomy to eOPBCS was 1.72 (95% CI 1.04-2.83). Meanwhile, HRs for DFS (1.11, 95% CI 0.60-2.08) and LRR (0.67, 95% CI 0.38-1.18) showed that there were no statistically significant differences but a trend toward lower recurrence rates with mastectomy.</div></div><div><h3>Conclusion</h3><div>eOPBCS demonstrates comparable to superior oncological outcomes to mastectomy in LABC, offering a promising option for selected patients. However, slightly elevated local recurrence rates, though not statistically significant, highlight the importance of careful patient selection and further research. High-quality prospective studies are essential to validate these findings and refine criteria for incorporating eOPBCS into routine clinical practice.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103869"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P088: IL2Rα is A Potential Biomarkers of Breast Cancer","authors":"W. Wang,&nbsp;L Zhu","doi":"10.1016/j.breast.2025.103957","DOIUrl":"10.1016/j.breast.2025.103957","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103957"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P016: Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With first or second line CDK 4/6 Inhibitors and Endocrine Therapy in Egypt","authors":"A. Kortoma,&nbsp;H. El Wakeel,&nbsp;N. Gobran,&nbsp;H Elghazawy","doi":"10.1016/j.breast.2025.103909","DOIUrl":"10.1016/j.breast.2025.103909","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103909"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P007: Optimal Perioperative Treatment for HER2-Positive Breast Cancer","authors":"H. Matsuzaki,&nbsp;H. Sakata,&nbsp;T. Aoyagi,&nbsp;M. Namura,&nbsp;T. Tamanuki,&nbsp;M. Iwai,&nbsp;N. Sasahara,&nbsp;S Mizuuchi","doi":"10.1016/j.breast.2025.103901","DOIUrl":"10.1016/j.breast.2025.103901","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103901"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P107: Digital breast tomosynthesis: unveiling residual disease postneoadjuvant chemotherapy","authors":"N. Javed,&nbsp;A. Munir,&nbsp;S. Khawaja,&nbsp;A. Huws,&nbsp;S. Khan,&nbsp;Y Sharaiha","doi":"10.1016/j.breast.2025.103973","DOIUrl":"10.1016/j.breast.2025.103973","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103973"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P100: Analysis of immune homeostasis (IH) and systemic inflammation (SI) using CDSS/«LeHaim»for monitoring luminal “B” breast cancer (BC)","authors":"D. Melnikov,&nbsp;I. Pushina,&nbsp;Y. Silacheva,&nbsp;O. Melnikova,&nbsp;V. Vaganov,&nbsp;A Lifshits","doi":"10.1016/j.breast.2025.103967","DOIUrl":"10.1016/j.breast.2025.103967","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103967"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}